The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses

The mRNA-based BNT162b2 vaccine from Pfizer/BioNTech was the first registered COVID-19 vaccine and has been shown to be up to 95% effective in preventing SARS-CoV-2 infections. Little is known about the broad effects of the new class of mRNA vaccines, especially whether they have combined effects on innate and adaptive immune responses. Here we confirmed that BNT162b2 vaccination of healthy individuals induced effective humoral and cellular immunity against several SARS-CoV-2 variants. Interestingly, however, the BNT162b2 vaccine also modulated the production of inflammatory cytokines by innate immune cells upon stimulation with both specific (SARS-CoV-2) and non-specific (viral, fungal and bacterial) stimuli. The response of innate immune cells to TLR4 and TLR7/8 ligands was lower after BNT162b2 vaccination, while fungi-induced cytokine responses were stronger. In conclusion, the mRNA BNT162b2 vaccine induces complex functional reprogramming of innate immune responses, which should be considered in the development and use of this new class of vaccines.

[1]  F. Poveda,et al.  Safety and immunogenicity , 2022 .

[2]  R. Blasczyk,et al.  Humoral and cellular immune responses against SARS-CoV-2 variants and human coronaviruses after single BNT162b2 vaccination. , 2021, medRxiv.

[3]  F. Baldanti,et al.  SARS-CoV-2 mRNA vaccine BNT162b2 elicited a robust humoral and cellular response against SARS-CoV-2 variants. , 2021 .

[4]  A. Huppert,et al.  Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals , 2021, Nature Medicine.

[5]  D. Montefiori,et al.  Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 , 2021, The New England journal of medicine.

[6]  T. de Oliveira,et al.  New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications , 2021, The New England journal of medicine.

[7]  S. Madhi,et al.  Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant , 2021, The New England Journal of Medicine.

[8]  D. Ho,et al.  Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.

[9]  P. Dormitzer,et al.  Neutralizing Activity of BNT162b2-Elicited Serum , 2021, The New England journal of medicine.

[10]  R. Scheuermann,et al.  Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees. , 2021, bioRxiv.

[11]  Jonathan C. Brown,et al.  Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine , 2021, The Lancet.

[12]  H. Mouquet,et al.  Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies , 2021, Nature Medicine.

[13]  P. Klenerman,et al.  Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern. , 2021 .

[14]  M. Huynen,et al.  Elevated mucosal antibody responses against SARS-CoV-2 are correlated with lower viral load and faster decrease in systemic COVID-19 symptoms , 2021, medRxiv.

[15]  D. Ho,et al.  Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 , 2021, bioRxiv.

[16]  P. Dormitzer,et al.  Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera , 2021, Science.

[17]  P. Miesen,et al.  Berberine and Obatoclax Inhibit SARS-Cov-2 Replication in Primary Human Nasal Epithelial Cells In Vitro , 2020, bioRxiv.

[18]  C. Akdis,et al.  Risk factors for severe and critically ill COVID‐19 patients: A review , 2020, Allergy.

[19]  S. Tahaghoghi-hajghorbani,et al.  The role of dysregulated immune responses in COVID-19 pathogenesis , 2020, Virus Research.

[20]  E. Walsh,et al.  Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.

[21]  C. Akdis,et al.  Risk factors for severe and critically ill COVID‐19 patients: A review , 2020, Allergy.

[22]  P. Dormitzer,et al.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[23]  D. Riel,et al.  Next-generation vaccine platforms for COVID-19. , 2020 .

[24]  J. Schuurs-Hoeijmakers,et al.  Presence of Genetic Variants Among Young Men With Severe COVID-19. , 2020, JAMA.

[25]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[26]  Zhenghao Xu,et al.  Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies , 2020, Frontiers in Immunology.

[27]  S. Rowland-Jones,et al.  Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.

[28]  R. Xavier,et al.  Defining trained immunity and its role in health and disease , 2020, Nature Reviews Immunology.

[29]  Bhupal Singh.  Influenza , 1916, Nature Reviews Disease Primers.

[30]  Trees Jansen,et al.  Trained Immunity or Tolerance: Opposing Functional Programs Induced in Human Monocytes after Engagement of Various Pattern Recognition Receptors , 2014, Clinical and Vaccine Immunology.

[31]  R. Xavier,et al.  Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. , 2012, Cell host & microbe.

[32]  Y. Lau,et al.  Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. , 2010, Vaccine.

[33]  D. Bernstein,et al.  Safety and Immunogenicity of Concurrent Administration of Live Attenuated Influenza Vaccine With Measles-Mumps-Rubella and Varicella Vaccines to Infants 12 to 15 Months of Age , 2008, Pediatrics.